@article{ref1,
title="Novel psychopharmacology for depressive disorders",
journal="Advances in experimental medicine and biology",
year="2021",
author="Fornaro, Michele and De Berardis, Domenico and Anastasia, Annalisa and Fusco, Andrea",
volume="1305",
number="",
pages="449-461",
abstract="Major depressive disorder carries a significant burden and a high risk for suicide. The need for more effective, safer, and faster-acting drugs is, therefore, compelling. The present chapter briefly assesses the most promising agents, focusing on non-monoamine-targeting compounds, namely, the glutamate antagonist ketamine and its enantiomer esketamine. A critical overview of the evidence and the pitfalls associated with current antidepressant drug development is likewise provided in the following text.<p /> <p>Language: en</p>",
language="en",
issn="0065-2598",
doi="10.1007/978-981-33-6044-0_22",
url="http://dx.doi.org/10.1007/978-981-33-6044-0_22"
}